Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis

International Journal of Bipolar Disorders

Volumn 2, Issue 1, 2014, Pages

  Severus, Emanuel ^a   Taylor, Matthew J ^b   Sauer, Cathrin ^a   Pfennig, Andrea ^a   Ritter, Philipp ^a   Bauer, Michael ^a   Geddes, John R ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anticonvulsants; Bipolar disorders; Lithium; Long term treatment; Meta analysis; Placebo; Randomized controlled trial; Systematic review

Indexed keywords

CARBAMAZEPINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; PLACEBO; QUETIAPINE; VALPROIC ACID;

ARTICLE; BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; MANIA; META ANALYSIS; MOOD DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 85056216381     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-014-0015-8     Document Type: Article

References (63)

1. Abou-Saleh MT, Coppen A (1986) Who responds to prophylactic lithium? J Affect Disord 10(2):115–125
2. Amsterdam JD, Shults J (2010) Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 167(7):792–800
3. Bauer M, Crossley NA, Gerber S, Bschor T (2006) The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in Neuropsychiatry. The Comprehensive Guide. Informa Healthcare, London, pp 109–128
4. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M (2014) Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28(4):331–342
5. Blackwell B, Shepherd M (1968) Prophylactic lithium: another therapeutic myth? An examination of the evidence to date. Lancet 1(7549):968–971
6. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JC-Y, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RMA, Wozniak PJ (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57(5):481–489
7. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60(4):392–400
8. Bschor T, Uhr M, Baethge C, Lewitzka U, Ising M, Erbe S, Winkelmann P, Ritter D (2013) Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. J Clin Psychopharmacol 33(1):38–44
9. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G (2001) Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 3:CD003013
10. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64(9):1013–1024
11. Calabrese JR, Vieta E, El-Mallakh R, Findling RL, Youngstrom EA, Elhaj O, Gajwani P, Pies R (2004) Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 56(12):957–963
12. Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J (2006) Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 4:CD003492
13. Cipriani A, Hawton K, Stockton S, Geddes JR (2013) Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346:f3646
14. Coxhead N, Silverstone T, Cookson J (1992) Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 85(2):114–118
15. Crossley NA, Müller-Oerlinghausen B, Glenn T, Bauer M (2006) The position of lithium in international and national guidelines for the treatment of mood disorders. In: Bauer M, Grof P, Müller-Oerlinghausen B (eds) Lithium in Neuropsychiatry. The Comprehensive Guide. Informa healthcare, London, pp 33–42
16. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
17. Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR (2006) Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry 67(11):1721–1728
18. Geddes JR, Miklowitz DJ (2013) Treatment of bipolar disorder. Lancet 381(9878):1672–1682
19. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM (2004) Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161(2):217–222
20. Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194(1):4–9
21. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375(9712):385–395
22. Goodwin GM (1994) Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 164(2):149–152
23. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65(3):432–441
24. Greenland S, Robins JM (1985) Estimation of a common effect parameter from sparse follow-up data. Biometrics 41(1):55–68
25. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1997) Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 43(2):151–161
26. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S, WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14(3):154–219
27. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, Chou JC, Wassef A, Risch CS, Hirschfeld RM, Nemeroff CB, Keck PE Jr, Evans DL, Wozniak PJ (2003) Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28(7):1374–1382
28. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA (2003) Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 64(2):144–151
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
30. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59(6):530–537
31. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A (1982) Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 39(9):1065–1069
32. Katona CL (1995) Refractory depression: a review with particular reference to the use of lithium augmentation. Eur Neuropsychopharmacol 5(Suppl):109–113
33. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK (2011) Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 199(1):57–63
34. Kessing LV, Hellmund G, Andersen PK (2012) An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol 26(5):644–652
35. Licht RW (2012) Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther 18(3):219–226
36. Licht RW, Severus E (2014) Letter to the editor: is it valid to break down results from long-term trials in bipolar disorder by polarity of relapses? Int J Bipolar Disord 2(8):ᅟ, Ref Type: Journal (Full). http://www.journalbipolardisorders.com/content/2/1/8
37. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H (2010) Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 12(5):483–493
38. Malhi GS, Tanious M, Das P, Berk M (2012) The science and practice of lithium therapy. Aust N Z J Psychiatry 46(3):192–211
39. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748
40. Markar HR, Mander AJ (1989) Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry 155:496–500
41. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379(9817):721–728
42. Melia PI (1968) Prophylactic lithium. Lancet 2(7566):519–520
43. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katsuki S, Leucht S, Cipriani A, Geddes JR, Kanba S (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1(5):351–359
44. Moher D, Liberati A, Tetzlaff J, Altmann DG, The Prima Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
45. Moncrieff J (1997) Lithium: evidence reconsidered. Br J Psychiatry 171:113–119
46. NIMH/NIH Consensus Development Conference statement (1985) Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel. Am J Psychiatry 142(4):469–476
47. Pfennig A, Bschor T, Baghai T, Braunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Möhrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M (2012) S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt 83(5):568–586
48. Prien RF, Caffey EM Jr, Klett CJ (1973) Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 28(3):337–341
49. Quitkin F, Rifkin A, Klein DF (1976) Prophylaxis of affective disorders. Current status of knowledge. Arch Gen Psychiatry 33(3):337–341
50. R Development Core Team. R (2005) A Language and Environment for Statistical Computing, Reference Index version 2.x.x. R Foundation for Statistical Computing, Vienna, Austria, Ref Type: Online Source
51. Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E (2011) Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci Ther 17(3):167–177
52. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332
53. Severus WE, Kleindienst N, Seemuller F, Frangou S, Moller HJ, Greil W (2008) What is the optimal serum lithium level in the long-term treatment of bipolar disorder- a review? Bipolar Disord 10(2):231–237
54. Severus WE, Lipkovich IA, Licht RW, Young AH, Greil W, Ketter T, Deberdt W, Tohen M (2010) In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005. Eur Psychiatry 25(8):443–449
55. Suppes T, Baldessarini RJ, Faedda GL, Tohen M (1991) Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 48(12):1082–1088
56. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M (1993) Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv Rev Psychiatry 1(3):131–144
57. The Cochrane Collaboration (2014) Review Manager (RevMan) [Computer program]. Version 5.3. The Nordic Cochrane Center, http://tech.cochrane.org/revman/about-revman-5, editors. ᅟ,Copenhagen, Ref Type: Online Source
58. Toerien M, Brookes ST, Metcalfe C, de Salis I, Tomlin Z, Peters TJ, Sterne J, Donovan JL (2009) A review of reporting of participant recruitment and retention in RCTs in six major journals. Trials 10:52
59. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162(7):1281–1290
60. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M (2009) The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 11(5):453–473
61. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (2011) Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 72(11):1452–1464
62. Wolf C, Berky M, Kovacs G (1997) Carbamazepine versus lithium in the prophylaxis of bipolar affective disorders. A randomised, double-blind 1-year study in 168 patients. Eur Neuropsychopharmacol 7(Supplement 2):S176, Ref Type: Journal (Full)
63. Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159(4 Suppl):1–50, http://www.ncbi.nlm.nih.gov/pubmed/11958165